BTIG Initiates Coverage On AC Immune with Buy Rating, Announces Price Target of $8

Benzinga · 05/31 09:50
BTIG analyst Thomas Shrader initiates coverage on AC Immune (NASDAQ:ACIU) with a Buy rating and announces Price Target of $8.